Pacific Edge Lands Draft Medicare Coverage for Its Only Two Bladder Tests
Draft Medicare LCD proposes coverage for Cxbladder Triage and Triage Plus — a pivotal moment for Pacific Edge
Pacific Edge (NZX/ASX: PEB) has noted the publication of a draft Local Coverage Determination (LCD), DL40378, by Medicare Administrative Contractor (MAC) Novitas, proposing Medicare coverage for urine-based biomarkers in patients with microhematuria. The associated Local Coverage Article (LCA) DA60424 provides explicit billing and coding guidance naming both Cxbladder Triage (0363U) and Cxbladder Triage Plus (0420U) as proposed reimbursable tests. Critically, the draft LCD establishes hematuria evaluation as a covered Medicare benefit for the first time, and no other urine-based biomarkers are named in the draft coding article, positioning Pacific Edge with an effective moat in the microhematuria diagnostics space.
When big ASX news breaks, our subscribers know first
What a Medicare LCD means — and why this one is different
How Medicare coverage policy works
A Local Coverage Determination (LCD) is a policy decision made by a Medicare Administrative Contractor (MAC) that governs which tests and procedures are reimbursable for Medicare patients within that contractor’s jurisdiction. In this case, Novitas, the MAC with jurisdiction over Pacific Edge’s laboratory in Pennsylvania, has published the draft LCD.
Once a draft LCD is published, it triggers a minimum 45-day “Notice and Comment” period during which the MAC holds a public meeting and accepts written submissions. Novitas must then publish a final LCD or withdraw the draft within 12 months of the draft publication date. If finalised, the LCD becomes effective 45 days after final publication. Prior to issuing this draft, Novitas convened a Contractor Advisory Committee (CAC) Meeting on 19 February 2026 to consider the clinical evidence for urine-based biomarkers.
Why the distinction in this draft LCD matters
The existing non-coverage LCD, L39365, titled “Genetic Testing in Oncology: Specific Tests,” applies to patients with cancer or substantiated suspicion of cancer. The new draft LCD explicitly distinguishes microhematuria patients as a separate, eligible population for urine-biomarker testing, separating them from the non-coverage group.
This is not a minor policy tweak. It closes the interpretive gap that previously left Pacific Edge without a clear reimbursement pathway for this patient population, representing a structural change in Medicare coverage policy.
The draft LCD process timeline is as follows:
- Draft published: 15 May 2026
- Notice and Comment period: Minimum 45 days (public meeting and written comments accepted)
- Final LCD deadline: Within 12 months of 15 May 2026
- Effective date if finalised: 45 days after final publication
Two tests covered, zero competitors — Pacific Edge’s commercial inflection point
Cxbladder Triage Plus at US$1,328 — the economics shift
Both Cxbladder Triage (0363U) and Cxbladder Triage Plus (0420U) are proposed as reimbursable under the draft policy. Importantly, no other urine-based biomarkers are included in the draft coding article, creating what management describes as a moat around the company’s microhematuria business.
The economic implications of Triage Plus coverage are material. The Medicare reimbursement rate for Cxbladder Triage Plus (0420U) is US$1,328 per test, representing a 75% improvement over the US$760 received for legacy Cxbladder products. Chief Executive Dr Peter Meintjes outlined four clinical and commercial reasons for transitioning customers to Triage Plus:
- Higher clinical utility compared to legacy products
- Broader applicability across a wider range of patient types
- Continued cost benefit for healthcare systems and payers
- Improved per-test economics for Pacific Edge, supporting a pathway to operating profitability
Chief Executive Dr Peter Meintjes
“The draft LCD and LCA confirm our position as the first mover and market leader in non-invasive diagnostics for microhematuria patients suspected of bladder cancer, and Pacific Edge now stands on the cusp of a major commercial inflection point with the only two tests covered for microhematuria evaluation.”
Scale of the Medicare opportunity — and the commercial payer tailwind
Once the LCD is finalised, it would directly enable reimbursement for over 66 million Medicare patients. The commercial payer opportunity extends considerably further: 223 million US lives are collectively insured by US commercial payers, and the clarity in the draft LCD’s coverage language is expected to provide a template for those payers to adopt in their own medical policies.
Pacific Edge also expects the development to provide a tailwind for international market adoption. Importantly, management has stated the company intends to engage with Novitas to seek reimbursement for Triage and Triage Plus on a claim-by-claim basis during the draft period, meaning the coverage news carries revenue relevance before any final LCD is published.
| Cxbladder Triage (0363U) | Cxbladder Triage Plus (0420U) | |
|---|---|---|
| Proposed Medicare coverage | Yes | Yes |
| Medicare reimbursement rate | US$760 (legacy) | US$1,328 |
| Patient population | Microhematuria | Broader range of patient types |
| Competitors named in draft LCA | None | None |
The next major ASX story will hit our subscribers first
Capital raise and the road ahead
Alongside the Medicare coverage news, Pacific Edge has an active Retail Offer open to eligible NZ-registered shareholders. The offer opened on 14 May 2026 and closes at 5:00pm NZST on 28 May 2026, allowing eligible shareholders to apply for up to NZ$50,000 of new shares at NZ$0.17 per share, with the potential to raise up to NZ$6 million (with oversubscription at Pacific Edge’s discretion).
This follows a separate and completed Placement. That Placement raised NZ$25.4 million at NZ$0.17 per share and closed on 12 May 2026, with over 90% of shares issued to existing Pacific Edge shareholders who were prioritised in the allocation. The two transactions are distinct and should not be combined into a single figure. Together, the capital raised positions the company to pursue its commercial strategy as it approaches what management considers a major inflection point.
Chief Executive Dr Peter Meintjes
“Creating value for investors through evidence development is a core expertise that Pacific Edge can repeat for Cxbladder Triage Plus, for Surveillance Plus and future products beyond bladder cancer.”
Looking ahead, Pacific Edge’s near-term pipeline centres on the commercialisation of Triage Plus, the advancement of Surveillance Plus, and the continued application of its Analytical Validity (AV), Clinical Validity (CV), and Clinical Utility (CU) evidence-generation framework. This framework underpins the company’s medical policy pathway and, as the Medicare LCD process demonstrates, its ability to drive reimbursement outcomes across key markets.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 active subscribers rely on it to stay ahead of market-moving developments. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.